SEARCH

SEARCH BY CITATION

References

  • Bicanic T, Harrison T, Niepieklo A, Dyakopu N & Meintjes G (2006) Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clinical Infectious Diseases 43, 10691073.
  • Boelaert JR, Goddeeris KH, Vanopdenbosch LJ & Casselman JW (2004) Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. AIDS 18, 12231224.
  • Bogaerts J, Rouvroy D, Taelman H et al. (1999) AIDS-associated cryptococcal meningitis in Rwanda (1983–1992): epidemiologic and diagnostic features. The Journal of Infection 39, 3237.
  • Breton G, Seilhean D, Cherin P, Herson S & Benveniste O (2002) Paradoxical intracranial cryptococcoma in a human immunodeficiency virus-infected man being treated with combination antiretroviral therapy. The American Journal of Medicine 113, 155157.
  • Chariyalertsak S, Sirisanthana T, Saengwonloey O & Nelson KE (2001) Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994–1998: regional variation and temporal trends. Clinical Infectious Diseases 32, 955962.
  • Chariyalertsak S, Supparatpinyo K, Sirisanthana T & Nelson KE (2002) A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clinical Infectious Diseases 34, 277284.
  • Cockcroft DW & Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16, 3141.
  • Coetzee D, Hildebrand K, Boulle A et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18, 887895.
  • Desmet P, Kayembe KD & De Vroey C (1989) The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS 3, 7778.
  • Duncombe C, Kerr SJ, Ruxrungtham K et al. (2005) HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. AIDS 19, 169178.
  • Egger M, May M, Chene G et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360, 119129.
  • French N, Gray K, Watera C et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16, 10311038.
  • French MA, Price P & Stone SF (2004) Immune restoration disease after antiretroviral therapy. AIDS 18, 16151627.
  • Greenland S & Drescher K (1993) Maximum likelihood estimation of the attributable fraction from logistic models. Biometrics 49, 865872.
  • Hajjeh RA, Conn LA, Stephens DS et al. (1999) Cryptocossis: population-based multistate active surveillance and risk factors for human immunodeficiency virus-infected persons. The Journal of Infectious Diseases 179, 449454.
  • Hakim JG, Gangaidzo IT, Heyderman RS et al. (2000) Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 14, 14011407.
  • Harries AD, Hargreaves NJ, Kemp J, Jindani A, Enarson DA & Maher D (2001) Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 357, 15191523.
  • Heyderman RS, Gangaidzo IT, Hakim JG et al. (1998) Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clinical Infectious Diseases 26, 284289.
  • Holmes CB, Losina E, Walensky RP, Yazdanpanah Y & Freedberg KA (2003) Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clinical Infectious Diseases 36, 652662.
  • Jenny-Avital ER & Abadi M (2002) Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clinical Infectious Diseases 35, e128133.
  • Kaplan JE, Masur H & Holmes KK (2002) Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. public health service and the infectious diseases society of America. MMWR Recommendations Reports 51, 152.
  • Lawn SD, Bekker LG, Myer L, Orrell C & Wood R (2005) Cryptococcal immune reconstitution disease: a major cause of early mortality in a South Africa antiretroviral program. AIDS 19, 20502052.
  • Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K & Dromer F (2005) Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 19, 10431049.
  • Moosa MY & Coovadia YM (1997) Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clinical Infectious Diseases 24, 131134.
  • Oursler KA, Moore RD & Chaisson RE (1999) Risk factors for cryptococcal meningitis in HIV-infected patients. AIDS Research Human Retroviruses 15, 625631.
  • Saag MS, Graybill RJ, Larsen RA et al. (2000) Practice guidelines for the management of cryptococcal disease. Clinical Infectious Disesases 30, 710718.
  • Stringer JSA, Zulu I, Levy J et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia – feasibility and early outcomes. The Journal of the American Medical Association 296, 782793.
  • Tanner DC, Weinstein MP, Fedorciw B, Joho KL, Thorpe JJ & Reller LB (1994) Comparison of commercial kits for detection of cryptococcal antigen. Journal of Clinical Microbiology 32, 16801684.
  • Tassie JM, Pepper L, Fogg C et al. (2003) Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda. Journal Acquired Immune Deficiency Syndromes 33, 411412.
  • Van Der Sande MAB, Schim van der Loeff MF, Aveika AA et al. (2004) Body mass index at time of HIV diagnosis: a strong and independent predictor of survival. Journal of Acquired Immune Deficiency Syndrome 37, 12881294.
  • Weidle PJ, Malamba S, Mwebaze R et al. (2002) Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients’ response, survival, and drug resistance. Lancet 360, 3440.
  • Woods ML II, MacGinley R, Eisen DP & Allworth AM (1998) HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 12, 14911494.